Top Neuro stories in 2023: FDA approves therapies for Alzheimer’s, Rett syndrome and more
Click Here to Manage Email Alerts
Healio Neurology looks back at the most-viewed stories throughout the year. Highlights include the FDA’s approval of Leqembi to treat Alzheimer’s disease and the regulatory body’s clearing of a blood test for concussions.
FDA clears blood test for concussion evaluation
The FDA has cleared Abbott’s laboratory blood test for concussion, making it the first commercially available test of its kind: Read more.
Neurological effects of long COVID: It is ‘not only a respiratory disease’
As the world continued to grapple with effects of the COVID-19 pandemic, many are still dealing with symptoms for months, even years, after their initial infection: Read more.
Q&A: Sleep experts warn against harmful effects of daylight saving time
The American Academy of Sleep Medicine issued a press release in early March in support of eliminating the twice-yearly time changes and advocates for legislation that restores permanent standard time: Read more.
FDA approves nasal spray for migraine in adults
The FDA approved Pfizer’s Zavzpret, a calcitonin gene-related peptide receptor antagonist nasal spray to treat migraine with or without aura in adults: Read more.
Quest announces availability of blood-based Alzheimer’s test
Quest Diagnostics has announced the availability of a blood-based test that assesses the risk of developing Alzheimer’s disease through amyloid-beta biomarkers: Read more.
FDA approves first Rett syndrome treatment for adult, pediatric patients
In mid-March, the regulatory body approved Daybue for Rett syndrome in patients aged 2 years and older, making it the first and only approved treatment for the genetic disorder: Read more.
FDA approves Leqembi for Alzheimer’s disease
The FDA granted Eisai full approval for Leqembi to treat adults with Alzheimer’s disease, making it the first amyloid-targeting antibody to be granted traditional approval: Read more.
Marriage linked to lower risk for dementia, mild cognitive impairment
Marriage was associated with a lower risk for dementia and mild cognitive impairment in later life, researchers reported in the Journal of Aging and Health: Read more.
Q&A: Hyperbaric oxygen therapy beneficial led to ‘significant cognitive improvement’ in long COVID
Healio spoke to Amir Hadanny, MD, PhD, chief medical officer and head of research at the Sagol Center for Hyperbaric Medicine and Research, based in Israel, about the use of hyperbaric medicine to optimize brain and body performance in individuals dealing with the after effects of COVID-19: Read more.
Participation in football linked to higher odds of Parkinson’s than other sports
Among a cohort of adult males who played sports, participation in football was associated with higher odds of self-reported parkinsonism or Parkinson’s disease, with length of play and level of play associated with higher odds of both: Read more.